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Abstract. In a retrospective case control study the preva-
lence of signs and symptoms of dialysis osteoarthropathy
was analysed. Cases and controls had received over 9
years of maintenance haemodialysis uninterrupted by
peritoneal dialysis or transplantation. The cases com-
prised 55 patients treated predominantly with poly-
acrylonitrile (AN69) dialysers. They were compared to a
matched group dialysed exclusively with cellulosic mem-
branes. Over 60% of all patients, cases and controls,
showed one or more signs of disabling osteoarthropathy,
with joint pains occurring more frequently in the older age
groups. Twenty-seven of the 55 cases who had received
less than 2 years of cellulosic membrane dialysis followed
by 7-12 years of AN69 dialysis tended to have a lower
prevalence of joint pains, carpal-tunnel syndrome and
bone cysts. However, no statistically significant differ-
ences were obtained compared to the matched control
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group dialysed exclusively on cellulosic membranes
(mostly cuprophane). The remaining 28 cases, who had
been treated for more than 2 years with cellulosic
membranes preceding the longer treatment period with
polyacrylonitrile dialysers, showed a prevalence similar to
that of their cellulosic controls.
This study thus shows little, if any, influence of the
two types of membranes on the prevalence of signs and
symptoms of p2-microglobulin amyloidosis.
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Introduction
Dialysis arthropathy has been recognised in recent years
as a severe and disabling condition with signs and symp-
toms developing after some 10 years on haemodialysis.
This new type of arthropathy is frequently accompanied
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by carpal-tunnel syndrome (CTS) and periarticular cysts
can be observed on X-ray examination. The full-blown
disease is characterised by joint pains and erosive
polyarthropathy as well as CTS and periarticular cysts.
Histological examination of synovia and/or bone cysts
usually reveals the presence of a special type of amyloid,
namely P2-microglobulin [1-6]. P2-Microglobulin is a
single polypeptide chain with a molecular weight of 11 800
daltons, which is eliminated almost entirely through the
kidney. In patients on haemodialysis, blood concen-
trations are markedly increased although this may be
influenced by residual renal function, number of years
on haemodialysis and type of membrane used for
haemodialysis.
The haemodialysis membrane polyacrylonitrile (AN69)
is well known for some very specific properties, including
its capacity to remove P2-microglobulin. It has been
claimed by some authors that no signs of haemodialysis-
associated amyloidosis could be found in patients who
had been dialysed for up to 10 years solely with this mem-
brane [7,8]. The possible relationship between types of
membrane and prevalence of this newly described disease
is difficult to evaluate in clinical research, as numbers
of comparable haemodialysis patients, treated for more
than 10 years and in whom the major discriminant is the
dialysis membrane, are small.
The Registry of the European Dialysis and Transplant
Association—European Renal Association (EDTA
Registry) designed a retrospective case control study to
investigate the prevalence of dialysis arthropathy in
two groups of patients. The major difference between
these two groups was the use of two different dialysis
membranes, namely a cellulosic membrane (mostly
cuprophane) and polyacrylonitrile (all AN69). Using
the EDTA Registry database of approximately 230 000
patient records, patients were identified who had been
treated by haemodialysis without interruption for 9 or
more years and who had used predominantly either AN69
or cuprophane membranes. A special questionnaire con-
cerning signs and symptoms of the disease was designed
and sent in late 1986 and in early 1987 to those centres
responsible for the care of these patients.
Materials and Methods
The cases were selected with the following inclusion
criteria:
1. The cause of end-stage renal failure had to be a
standard primary renal disease (glomerulonephritis,
pyelonephritis/interstitial nephritis, toxic nephropathy,
cystic renal diseases, chronic renal failure of uncertain
aetiology). Thus patients with systemic diseases, diabetic
nephropathy, amyloidosis and myeloma, as well as
carcinoma, were excluded.
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2. Haemodialysis, started in 1976 or earlier, had to be
the sole method of treatment from the start of renal
replacement therapy (RRT). The treatment sequence had
not to be interrupted by transplantation, CAPD or
recovery of renal function until 31 December 1985.
3. Patients had to be registered and alive on 31
December 1985.
4. The cases had to be on polyacrylonitrile (AN69)
dialysers starting in 1981 or earlier.
A total of 296 questionnaires were sent out for patients
who met the first three of these inclusion criteria and for
whom an AN69 dialyser was recorded as the most com-
monly used dialyser in 1985. Manual checking of the
returns allowed the identification of 81 cases who had
been treated with AN69 dialysers since 1981 or earlier.
For each AN69 case, a control patient was selected from
the EDTA Registry file using Registry software developed
for this purpose. Cases and controls had to be of the same
sex and come from the same country but the age of the
control patient could vary ± five years of that of the AN69
case. Potential control cases were listed and then an
individual control case was selected by using a random
number table. The mean number of controls for each case
was 25 (median: 24) and varied between 1 and 50. No
control patient could be found for two of the 81 cases. Of
the 79 control questionnaires that were sent out, 55 could
be included. In 27 of the 55 AN69 cases, dialysis by AN69
had been preceded by less than 2 years and in 28 by more
than 2 years of dialysis with a cellulosic membrane,
mostly cuprophane, before switching to AN69. Statistical
analysis was performed using the %2 test with Pearson's
correction and the rank sum test.
The questionnaire for each patient requested infor-
mation on presence or absence of joint pains, evidence of
CTS, radiological evidence of periarticular cystic bone
lesions, radiological evidence of erosive polyarthropathy,
histological evidence of amyloid and serum P2-
microglobulin level if available. For each patient, data
concerning start of treatment and type of membrane used
had to be confirmed by the centre.
Results
Table 1 shows the patient characteristics of the two AN69
groups and their cuprophane controls. Median ages were
matched, as were the number of years that patients had
been treated by haemodialysis. The number of years that
patients had been treated with AN69 or cuprophane is
also given and a differentiation is made between those
treated with cellulosic membranes for less than 2 years
before switching to AN69 versus those previously treated
for more than 2 years with cellulosic membrane. It should
be noted that the number of years in Table 1 relate to
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Table 1. Median age and duration of uninterrupted maintenance haemodialysis on 31 December 1985 in two groups
of patients with the membrane type (cellulosic vs AN69) as the most common discriminant
Median age
Years on dialysis
(median range)
Years on same membrane
(median range)
AN69
<2 years cellulosic
membrane
(27 cases)
58
10(9-12)
10(7-12)
Cuprophane
(27 controls)
59
10(9-12)
10(7-12)
AN69
> 2 years cellulosic
membrane
(28 cases)
60
12(10-17)
7(4-11)
Cuprophane
(28 controls)
60
11(9-17)
11(9-17)
Table 2. Prevalence of signs and symptoms of dialysis osteoarthropathy after long-term haemodialysis in patients
treated predominantly with AN69 or with cellulosic membranes
AN69
(< 2 years
cell, membr.)
P value Controls AN69
(> 2 years
cell, membr.)
P value Controls
Joint pains
CTS
Cysts
Erosive arthropathy
13/26
7/26
6/26
6/25
0.17
0.38
0.23
0.89
18/26
10/26
10/26
6/24
21/25
11/27
10/27
7/27
0.71
0.43
0.77
0.15
20/25
14/27
9/27
12/27
Cases treated with cellulosic membranes for less than 2 years, and those treated for more than 2 years, before
switching to AN69 are recorded separately
31 December 1985, whilst collection of clinical data by
completing the questionnaires occurred 12-18 months
later.
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Fig. 1. Prevalence of signs and symptoms of dialysis osteoarthropathy in
the 27 AN69 cases with less than 2 years haemodialysis on cellulosic
membranes and their controls.
Joint pain CTS Cysts Erosive
arthropathy
Symptoms
Fig. 2. Prevalence of signs and symptoms of dialysis osteoarthropathy in
the 28 AN69 cases with more than 2 years haemodialysis on cellulosic
membranes and their controls.
The prevalence of signs and symptoms of dialysis-
associated amyloidosis is shown in Table 2 and Figs 1 and
2. Although, as shown in Table 2, a slightly lower preva-
lence was recorded for joint pains, CTS, and bone cysts in
the AN69 cases, no statistically significant differences
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were obtained, whether patients were dialysed for less, or
more, than 2 years with cellulosic membranes before
switching to AN69.
The distribution of age groups is given for combined
groups of cases and controls as mentioned in Table 2 and
for specific symptoms of dialysis-associated arthropathy
in Fig. 3. x-square analysis shows a significant relation-
ship between age and joint pains (/><0.01). For the other
symptoms of dialysis-related osteoarthropathy x-square
analysis did not show a significant relationship with age
(carpal-tunnel syndrome, P > 0.20; cysts, P > 0.20; erosive
arthropathy, P>0.95). P2-Microglobulin values were
given for only a minority of patients and thus it was not
possible to make a meaningful comparison between cases
and controls for this variable. A more detailed analysis,
using Haldane's test, shows the proportional contribution
of age for those with and without joint pains (Fig. 4).
This test confirms a statistically significant relationship
(/•<0.04). There was no difference in the median and
mean time on dialysis for patients with and without joint
pains (median: 10 years for both groups).
Cumulative proportion
1.0
30 40
• lolnt pains
• CTS
• cysts
• erosive arthropathy
30-39 40-49 50-59 60-69
Age at 31 December 1985
> 70
Fig. 3. Prevalence of signs and symptoms of dialysis associated
osteoarthropathy according to age at 31 December 1985 for all cases and
controls.
Discussion
Dialysis arthropathy or haemodialysis-associated
amyloidosis contributes to disability in dialysis patients.
This painful bone and joint disease has been attributed by
many investigators to the formation of amyloid deposits
50 60
Age (years) at 31 December 19S5
Fig. 4. A cumulative proportion with age of dialysis patients with and
without joint pains according to their ages on 31 December 1985.
consisting mainly of P2-microglobulin [5,6]. However,
other causative mechanisms have been proposed, such as
deposits of haemosiderin [9].
It is beyond doubt that blood concentrations of P2-
microglobulin are greatly elevated in haemodialysis
patients and that these concentrations can be influenced
by the type of membrane used for haemodialysis. The use
of more porous membranes, such as AN69, yield a 50%
reduction in blood concentrations in comparison with
cuprophane membranes. However, even with the use of
more porous dialysis membranes, blood concentrations
for P2-microglobulin can be as much as 20-fold the
normal values [8].
It has been reported that the number of cases of
arthropathy in patients dialysed with AN69 membranes
was smaller than in patients treated with cuprophane
membranes. However, no rigorously comparable con-
trols were available and patients were not evaluated for
grafting, type of renal disease and sex [7]. In view of the
fact that only 55 pairs of patients within the EDTA
Registry database fulfilled the criteria of this case control
study, and no more than 27 cases had less than 2 years of
cellulosic membrane dialysis, it is not surprising that no
properly controlled data are available.
Some conclusions can be drawn from this study despite
its shortcomings such as its multicentre character, the
small number of patients and, as yet, a poorly defined
syndrome. More than 60% of all the patients reported in
this study, and who had been dialysed for at least 9 years,
suffered from painful osteoarticular disease. Although the
severity of the disease and the time of onset of symptoms
were not evaluated, of all signs and symptoms the preva-
lence of joint pains differed between age groups (Figs 3,4).
However, more data are needed to validate these findings.
The 27 AN69 cases who had received initial treatment
with cellulosic membranes for less than 2 years tended to
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have a lower prevalence of some signs and symptoms
of p2-microglobulin amyloidosis than the 27 controls
(Fig. 1). However, differences in prevalence did not reach
statistical significance. The 28 cases with more than two
years' dialysis solely on cellulosic membranes before they
went on to AN69 dialysis showed minor and inconsistent
differences compared to the control group on cuprophane
alone (Fig. 2).
The use of different membranes for haemodialysis
is influenced by doctors' desire to eliminate uraemic
toxins, prevent acute side-effects and reduce long-term
morbidity. If a clear clinical advantage can be estab-
lished for one type of membrane then this will be chosen
irrespective of its cost. One of the most important long-
term sequelae of haemodialysis seems to be dialysis
osteoarthropathy (or dialysis-associated amyloidosis).
However, in this retrospective case control study it could
not be proven that patients dialysed for more than
10 years with cuprophane, a dialysis membrane with low
porosity, would suffer more frequently from this disease
than those dialysed predominantly with the highly porous
polyacrylonitrile (AN69) membrane. Of the symptoms
characterising this condition, joint pains were found more
frequently in older patients. This suggests a link with age
which is worthy of a more detailed study.
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